Savaysa

prophylaxis of systemic embolism, Cerebrovascular accident prophylaxis, Pulmonary Embolism + 4 more

Treatment

9 FDA approvals

20 Active Studies for Savaysa

What is Savaysa

Edoxaban

The Generic name of this drug

Treatment Summary

Edoxaban is a type of medicine called a Novel Oral Anti-Coagulant (NOAC). It helps prevent blood clots by inhibiting a key protein in the coagulation cascade, called factor Xa. It is used to reduce the risk of stroke in people with nonvalvular atrial fibrillation and to treat deep vein thrombosis and pulmonary embolism. Edoxaban is preferred over warfarin because it starts working quickly, is easier to take and monitor, and has fewer side effects.

Savaysa

is the brand name

image of different drug pills on a surface

Savaysa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Savaysa

Edoxaban

2015

3

Approved as Treatment by the FDA

Edoxaban, otherwise called Savaysa, is approved by the FDA for 9 uses including Non Valvular Atrial Fibrillation (nv AF) and Deep Vein Thrombosis .

Non Valvular Atrial Fibrillation (nv AF)

Deep Vein Thrombosis

Systemic Embolism

prophylaxis of systemic embolism

Deep Vein Thrombosis

Pulmonary Embolism

Cerebrovascular accident prophylaxis

Stroke

Atrial Fibrillation

Effectiveness

How Savaysa Affects Patients

Edoxaban increases the time it takes for blood to clot, as measured by tests such as aPTT, PT, and INR.

How Savaysa works in the body

Edoxaban stops a chemical reaction in the body that helps create a blood clot. It specifically stops the enzyme factor Xa from working, which prevents clotting.

When to interrupt dosage

The advised dose of Savaysa is contingent upon the identified condition, including Deep Vein Thrombosis, Cerebrovascular accident prophylaxis and Deep Vein Thrombosis (DVT). The measure of dosage fluctuates as per the procedure of delivery outlined in the table underneath.

Condition

Dosage

Administration

prophylaxis of systemic embolism

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Cerebrovascular accident prophylaxis

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Pulmonary Embolism

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Atrial Fibrillation

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Deep Vein Thrombosis

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Systemic Embolism

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Stroke

, 15.0 mg, 30.0 mg, 60.0 mg

, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

Savaysa Contraindications

Condition

Risk Level

Notes

Hemorrhage

Do Not Combine

There are 20 known major drug interactions with Savaysa.

Common Savaysa Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The risk or severity of bleeding can be increased when Edoxaban is combined with (R)-warfarin.

(S)-Warfarin

Major

The risk or severity of bleeding can be increased when Edoxaban is combined with (S)-Warfarin.

4-hydroxycoumarin

Major

The risk or severity of bleeding can be increased when Edoxaban is combined with 4-hydroxycoumarin.

Abciximab

Major

The risk or severity of bleeding can be increased when Edoxaban is combined with Abciximab.

Acenocoumarol

Major

The risk or severity of bleeding can be increased when Edoxaban is combined with Acenocoumarol.

Savaysa Toxicity & Overdose Risk

Stopping edoxaban treatment before it is complete could lead to dangerous blood clots. Edoxaban also increases the risk of serious bleeding, such as bleeding in the brain or stomach. Patients need to be aware of signs of minor and major bleeding and know when to seek medical help. It is also important to avoid taking other blood thinners, anti-platelets, or clot-busting medications with edoxaban as this increases the risk of bleeding.

image of a doctor in a lab doing drug, clinical research

Savaysa Novel Uses: Which Conditions Have a Clinical Trial Featuring Savaysa?

61 active clinical trials are examining the potential of Savaysa in alleviating Stroke, Deep Vein Thrombosis (DVT) and Systemic Embolism.

Condition

Clinical Trials

Trial Phases

prophylaxis of systemic embolism

0 Actively Recruiting

Cerebrovascular accident prophylaxis

0 Actively Recruiting

Stroke

6 Actively Recruiting

Not Applicable, Phase 1

Deep Vein Thrombosis

9 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 4

Pulmonary Embolism

22 Actively Recruiting

Early Phase 1, Phase 4, Phase 3, Not Applicable

Systemic Embolism

2 Actively Recruiting

Not Applicable

Atrial Fibrillation

2 Actively Recruiting

Not Applicable

Savaysa Reviews: What are patients saying about Savaysa?

5

Patient Review

3/16/2016

Savaysa for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

I bruises all over my body pretty easily, and this medication has made it much worse. I'm glad it will be out of my system in a week.

5

Patient Review

6/19/2015

Savaysa for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

4

Patient Review

2/25/2018

Savaysa for Blood Clot in Lung

This drug helped thin my blood, but unfortunately I had to stop taking it because the side effect of kidney pain was too much to bear.

4

Patient Review

12/12/2015

Savaysa for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

3

Patient Review

8/10/2016

Savaysa for Treatment to Prevent Blood Clots in Chronic Atrial Fibrillation

After starting this medication, my father-in-law developed congestive heart failure. Has anyone else experienced this side effect?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about savaysa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Savaysa?

"Additionally, people may experience bleeding,, easy bruising,, nosebleeds,, rash,, abnormal liver function tests, and., low red blood cell count (anemia)."

Answered by AI

Is Savaysa an anticoagulant?

"Edoxaban is a pill taken once daily that helps reduce the risk of stroke and blood clots in people with nonvalvular atrial fibrillation. It can also be used to treat deep vein thrombosis and pulmonary embolism after initial treatment with a blood thinner given through an IV."

Answered by AI

What is the drug Savaysa used for?

"SAVAYSA can be used to treat blood clots in the veins of your legs or lungs after you have already been treated with an injectable blood thinner for 5 to 10 days."

Answered by AI

Is Savaysa the same as eliquis?

"Eliquis prevents blood clots from forming, while Savaysa can prevent blood clots from forming without any food restrictions or frequent blood tests. However, the effects of Savaysa will be very difficult to reverse if someone overdoses on the drug."

Answered by AI

Clinical Trials for Savaysa

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA

The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.

Phase 4
Waitlist Available

Inova Alexandria Hospital

Image of Brooks Rehabilitation Clinical Research Center in Jacksonville, United States.

Q Therapeutic System for Stroke

18 - 80
All Sexes
Jacksonville, FL

This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.

Recruiting
Has No Placebo

Brooks Rehabilitation Clinical Research Center

Emily Fox, PT, DPT, MHS, PhD

BrainQ Technologies Ltd.

Have you considered Savaysa clinical trials?

We made a collection of clinical trials featuring Savaysa, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Portable Dynamic Chest X-Ray for ICU Patients

18+
All Sexes
Boston, MA

Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU. The goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care. Participants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Gyorgy Frendl, MD PhD

Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL

The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.

Phase 4
Waitlist Available

RUSH University Medical Center

Bulent Arslan, MD

Have you considered Savaysa clinical trials?

We made a collection of clinical trials featuring Savaysa, we think they might fit your search criteria.
Go to Trials
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Have you considered Savaysa clinical trials?

We made a collection of clinical trials featuring Savaysa, we think they might fit your search criteria.
Go to Trials